Why the study?
Does prophylactic cyclosporine A improve lung architecture in a neonatal mouse model of increased pulmonary blood flow?
Does prophylactic cyclosporine A improve lung architecture in a neonatal mouse model of increased pulmonary blood flow?
Answers are grounded in this paper and cite their sources.
Increased pulmonary blood flow in congenital heart disease acts as a molecular disruptor of postnatal lung maturation, which can be partially rescued by time-sensitive immunomodulatory therapy.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Zhong et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: